Junichi Sakamoto

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

Jun Imagawa, Hideo Tanaka, Masaya Okada et al. · The Lancet Haematology · 2015 · 297 citations

Hematological Malignancy, Medicine, Chronic Myeloid Leukaemia +11

Impact of postoperative complications on the colorectal cancer survival and recurrence: analyses of pooled individual patients’ data from three large phase III randomized trials

Toru Aoyama, Koji Oba, Michitaka Honda et al. · Cancer Medicine · 2017 · 121 citations · Full text

Antibiotic use in Vietnamese hospitals: A multicenter point-prevalence study

Trương Anh Thư, Mahbubur Rahman, Susan Coffin et al. · American Journal of Infection Control · 2012 · 113 citations

Antibiotics, Healthcare-associated Infection, Patient Safety +5

Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy

Pilar Garin‐Chesa, Junichi Sakamoto, S Welt et al. · International Journal of Oncology · 1996 · 99 citations

Immunology, Organ-specific Expression, Pathology +19

Analysis of the specificity of five murine anti-blood group A monoclonal antibodies, including one that identifies type 3 and type 4 A determinants

Koichi Furukawa, Henrik Clausen, Sen‐itiroh Hakomori et al. · Biochemistry · 1985 · 95 citations